Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues

#1363

Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.

Aim(s): To assess the effect of Peptide Receptor Radionuclide Therapy (PRRT) on refractory carcinoid syndrome.

Materials and methods: A retrospective analysis included 35 patients with advanced NETs and refractory carcinoid syndrome despite maximum doses of SSAs, who had Lutetium177 DOTA Octreotate PRRT. Pre- and post- PRRT assessment of flushing, bowel frequency and 24h urine 5-Hydroxyindoleacetic Acid (5-HIAA) was performed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Koffas A

Authors: Koffas A, Popat R, Dimitriou G, Quigley A, Navalkissoor S,

Keywords: PRRT, carcinoid syndrome,